INTRODUCTION
============

von Willebrand disease (VWD) is the most common inherited bleeding disorder and is caused by deficient or defective plasma von Willebrand factor (VWF) \[[@B1]\]. High-molecular-weight (HMW) VWF is essential for platelet-dependent primary hemostasis. It protects factor VIII (FVIII) from degradation and delivers it to sites of vascular damage for secondary hemostasis \[[@B2]\]. The human *VWF* gene is located over 178 kb on chromosome 12p13.3 and comprises 52 exons \[[@B3]\]. The translated VWF molecule contains 2,813 amino acids, comprising a signal peptide, a propeptide, and a mature subunit of 2,050 amino acids \[[@B2]\]. The protein has four different domains arranged in the order of D1-D2-D′-D3-A1-A2-A3-D4-C1-C2-C3-C4-C5-C6-CK \[[@B4]\].

VWD is classified into type 1, 2, or 3. Types 1 and 3 are quantitative defects of VWF, in which VWF levels are partially reduced (type 1) or undetectable (type 3) \[[@B5]\]. Type 2 includes qualitative defects and is divided into 2A, 2B, 2M, and 2N. Correct diagnosis and classification of VWD is important to provide these patients with the best therapeutic approaches \[[@B6]\]. Molecular analysis of *VWF* is useful for the diagnosis and classification of VWD \[[@B7]\]. Most *VWF* variants can be detected by sequencing analyses; they occur throughout the *VWF* gene in type 1 and 3 VWD, while type 2 variants tend to be localized to particular functional domains \[[@B2][@B7]\]. Recently, the clinical use of multiplex ligation-dependent probe amplification (MLPA) analysis has been suggested for detecting dosage variants in sequence variant-negative cases of VWD and other bleeding disorders \[[@B7][@B8][@B9]\].

Recent studies on population-based sequencing data have demonstrated considerable ethnic diversity in the coding sequence of *VWF* (<http://exac.broadinstitute.org>, last updated in August 2016, <http://evs.gs.washington.edu/EVS>, last updated in May 2015) \[[@B10]\]. So far, only Song, et al. \[[@B11]\] have examined the genetic background of VWD in Korean patients. They performed direct sequencing of limited exons in *VWF*, focusing on locations containing known variants. We delineated the variant spectrum of the *VWF* gene in Korean patients with VWD, through a comprehensive molecular genetic investigation involving the whole coding/junction sequences of *VWF* and MLPA analysis.

METHODS
=======

Patients
--------

Twenty-two unrelated Korean patients with VWD were prospectively recruited from August 2014 to December 2017 from the Korea Hemophilia Foundation Clinic (Seoul), Ulsan University Hospital (Ulsan), Inha University Hospital (Incheon), and Kyungpook National University Hospital (Daegu) ([Table 1](#T1){ref-type="table"}). Their median age was 23 years (range, 28 months--64 years), and the male: female ratio was 1.2:1. VWD was diagnosed based on clinical and laboratory investigation following the International Society on Thrombosis and Haemostasis-Scientific and Standardization Committee VWF guidelines \[[@B5]\].

Bleeding score was assessed, and coagulation tests were performed at the institutions where the patients were recruited \[[@B12]\]. For each patient, two 3 mL dipotassium EDTA (K2 EDTA) tubes and three 2 mL 3.2% sodium citrate tubes were obtained. Complete blood count was performed within four hrs at room temperature. If plasma testing was not possible within four hrs at room temperature, then samples were frozen, at or below −20℃, and analyzed within three months. VWF antigen (VWF:Ag) and VWF activity were measured using an immunoturbidimetric assay with HemosIL von Willebrand Factor Antigen (Instrumentation Laboratories, Bedford, MA, USA) and HemosIL von Willebrand Factor Activity (Instrumentation Laboratories), according to the manufacturer\'s instructions. Ristocetin-induced platelet aggregation was measured in platelet rich plasma using an aggregometer (Chrono-Log, Havertown, PA, USA) with a ristocetin concentration of 1.0 mg/mL. For multimer analysis, non-reduced plasma samples were analyzed using sodium dodecyl sulfate-agarose electrophoresis (0.7 and 1.2%), and multimer was detected after blotting using anti-VWF antibody, biotinylated secondary antibody, avidin horseradish peroxidase, and bromophenol-blue. FVIII activity (FVIII:C) was measured using a standard one-stage clotting assay with the ACL 9000 Analyzer (Instrumentation Laboratories).

Molecular genetics analyses
---------------------------

### Direct sequencing analyses

Peripheral blood samples were collected after obtaining written informed consent from each patient or his/her parent(s) according to the Declaration of Helsinki. The study protocol was approved by the Institutional Review Board of Samsung Medical Center, Seoul, Korea (\# 2011-12-023). Molecular genetic analyses were performed at Samsung Medical Center. Genomic DNA was extracted from leukocytes using the Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA) following the manufacturer\'s instructions, within three days when blood was stored at room temperature or within 10 days when blood was stored at 4℃. Direct sequencing analyses were performed on all exons and exon/intron boundary sequences, as well as the promoter region of the *VWF* gene, using the BigDye Terminator Cycle Sequencing V1.1 Ready Reaction kit and an ABI 3130 DNA sequencer (Applied Biosystems, Foster City, CA, USA). To ensure specific amplification, we used previously reported primers considering the differences between the *VWF* genomic sequence and the highly homologous pseudogene sequence \[[@B13]\]. To identify sequence variations, patient sequences were compared with the reference sequence (GenBank accession number NM_000552.4) using the DNA sequence assembly software Sequencher 4.10.1 (Gene Codes Corporation, Ann Arbor, Michigan, USA). Any variations detected were described according to the guidelines of the Human Genome Variation Society \[[@B14]\].

### MLPA analyses

When no sequence variants were observed in sequencing or when PCR failure was observed in one or more exons, large dosage variants were searched using MLPA with a commercially available kit (SALSA MLPA PO11-B1 and PO12-B1 kit, MRC-Holland, Amsterdam, The Netherlands), according to the manufacturer\'s protocols \[[@B15]\]. Data were analyzed using the GeneMarker software (SoftGenetics, LLC, State College, PA, USA).

### Variant interpretation and classification

Variants detected were interpreted and classified according to the American College of Medical Genetics and Genomics/Association for Molecular Pathology standards and guidelines \[[@B16]\]. To interpret sequence variants in the *VWF* gene, we referred to the following public variant/variation databases: VWFdb (<https://grenada.lumc.nl/LOVD2/VWF>, last updated in March 2017), HemoBase (<http://www.hemobase.com/vwf>, last updated in 2012), dbSNP (<https://www.ncbi.nlm.nih.gov/projects/SNP>, last updated in April 2018), 1000 Genomes database (<https://www.ncbi.nlm.nih.gov/variation/tools/1000genomes>, last updated in May 2013), Exome Aggregation Consortium ExAC (<http://exac.broadinstitute.org>, last updated in August 2016), and the National Heart Lung and Blood Institute\'s Exome Sequencing Project (<http://evs.gs.washington.edu/EVS>, last updated in May 2015). We also referred to variation data from 622 ethnicity-matched control subjects of Korean descent in the Korean Reference Genome Database (<http://coda.nih.go.kr/coda/KRGDB/index.jsp>, last updated in September 2018). In addition, we performed in silico analysis for novel candidate missense variants, using Sorting Intolerant From Tolerant (SIFT, <http://sift.jcvi.org>, last updated in January 2015), Polymorphism Phenotyping v2 (PolyPhen-2, <http://genetics.bwh.harvard.edu/pph2/>, last updated in January 2016), and Align-GVGD (<http://agvgd.hci.utah.edu/agvgd_input.php>, last updated in September 2014). Collectively, variants were classified as pathogenic variant (PV), likely pathogenic variant (LPV), variant of uncertain significance (VUS), likely benign variant, or benign variant \[[@B16]\]. We considered PV, LPV, and VUS as putative disease-causing variants.

### Statistical analyses

We compared VWF:Ag level between patients harboring one or more variants and patients without an identified variant, using an independent t-test and SPSS 18.0 (PASW Statistics, Chicago, IL, USA).

RESULTS
=======

Fifteen patients met the criteria of type 1 VWD. Six patients were compatible with type 2 VWD (five 2A and one 2M). One patient was diagnosed as having type 3 VWD ([Table 2](#T2){ref-type="table"}). No patients had type 2B or 2N VWD. A family history of bleeding diathesis was documented in nine patients (41%): four with type 1 and five with type 2 (four with 2A and one with 2M).

We identified putative disease-causing variants in 15 patients (68%): 14 patients with a single heterozygous variant and one patient with two heterozygous variants. The variants included 13 missense variants, one small insertion, and one splicing variant. All variants were unique, except for p.C858W, which was detected in two patients. MLPA analysis in seven patients without sequence variants by sequencing did not reveal any dosage variants. Four variants were novel: p.S764Efs^\*^16, p.C889R, p.C1130Y, and p.W2193C.

Of the 15 patients with type 1 VWD, nine patients had *VWF* variants (variant detection rate 60%). Eight patients had a single heterozygous variant, and one patient (P20) had two known missense variants. The variants in type 1 VWD were distributed throughout the *VWF* region with the highest frequency in the D3 domain. The majority were missense variants (N=9; 90%), including three novel variants (p.C889R, p.C1130Y, and p.W2193C). One novel small insertion variant (c.2289dupG) in one patient (P11) was predicted to cause a reading frame shift and subsequently, premature termination of the VWF protein. All six patients with type 2 VWD were heterozygous for a known *VWF* variant (variant detection rate 100%): five missense variants and one splicing variant. No sequence or dosage variants were detected in one patient with type 3 VWD (P2).

In silico analyses were performed to predict the pathogenicity of three novel putative missense variants (p.C889R, p.C1130Y, and p.W2193C; [Table 3](#T3){ref-type="table"}). Both SIFT and PolyPhen algorithms showed all novel missense variants most likely cause damage. The Align-GVGD software predicted that all novel missense variants most likely interfere with protein function.

DISCUSSION
==========

We investigated molecular defects of *VWF* in 22 unrelated Korean patients with VWD recruited from multiple institutions in Korea with a nationwide distribution. The patients consisted of 15 type 1 (68%), six type 2 (27%), and one type 3 (5%), which is largely compatible with the distribution in previous studies in western countries and Korea \[[@B11][@B17]\]. Song, et al. \[[@B11]\] screened exons 12, 14, 16, 18, 19, 20, 24, 26, 27, 28, and 52 in Korean patients with VWD. They reported variant detection rates of 11%, 30%, and 0% for type 1, type 2, and type 3 VWD, respectively. We increased the variant detection rate by involving whole exons of *VWF*. Our results revealed the molecular genetic profile and genotype-phenotype correlations in Korean patients with VWD, albeit in a limited number of patients.

Except for one splicing variant and one small insertion variant, all remaining variants were missense variants. The variants in type 1 VWD were spread throughout the *VWF* gene, in line with previous reports that the variants responsible for type 1 VWD include missense (70%), splice (9%), transcription (8%), and other deleterious variants (13%) \[[@B2][@B18]\]. The VWF:Ag level was variable in our patients with type 1 VWD, ranging from 6 to 73 IU/dL (mean VWF:Ag 28.7 IU/dL). The VWF:Ag level in the patients without variants was higher than that in patients with variants (39.0 vs. 22.2 IU/dL), but not significantly (*P*=0.113). This is also in line with previous studies demonstrating that the genetic determinants in milder cases of VWD are more complex and might involve other factors outside the *VWF* locus \[[@B18][@B19][@B20]\].

According to a French study and the VWFdb, variants in type 2A VWD are mostly located in A domains (\~80%) \[[@B21]\]. Of the five patients with type 2A VWD in our study, three had a variant typically found in domains A1/A2 (P7, P17, and P22), while the variants in the remaining two patients, P3 and P5, were a splicing variant in the donor site of IVS26 and a missense variant in the D′ domain (p.C858W), respectively. p.C858W was the only recurrent variant in our study, detected in two patients, type 1 (P15) and type 2A (P5) VWD ([Table 2](#T2){ref-type="table"}). Of note, p.C858W was previously reported in a Korean patient with type 1 VWD \[[@B11]\]. Other missense variants affecting the C858 residue, p.C858S and p.C858F, are well known for their association with type 2N VWD (VWFdb). Type 2N VWD is inherited in an autosomal recessive manner and heterozygous carriers of type 2N VWD are often asymptomatic and most of laboratory findings could be normal except for the VWF:FVIIIB/VWF:Ag ratio \[[@B22]\]. Thus, the presence of p.C858W in Korean patients with VWD demonstrates a pleiotropic effect of missense variants involving the C858 residue. To our knowledge, the IVS26+1G\>A variant in P3 is the first splicing variant in type 2 VWD. As other forms of premature termination variants, such as frameshift and nonsense in type 2, have been reported, it is plausible that deleterious variants due to a splicing defect could also cause type 2A VWD (VWFdb).

Type 2M accounts for a relatively small proportion of VWD patients, with a limited number of variants being reported to date. Most variants are missense or in-frame deletion variants in exon 28 (D3-A1) (VWFdb). We identified only one patient with type 2M, carrying a missense variant in the A1 domain. Finally, we identified one type 3 VWD patient (P2). While the variant detection rate for type 3 VWD has been approximately 90% \[[@B2]\], we did not detect any variants in this patient by sequencing or MLPA. Possible explanations include deep intronic variants affecting the expression of the VWF protein or large rearrangement variants without dosage aberrations. Furthermore, as the patient had no family history of bleeding diathesis, we could not rule out the possibility of acquired VWD.

All in silico analysis tools predicted that the three novel missense variants (p.C889R, p.C1130Y, and p.W2193C) detected in patients with type 1 VWD exert damaging effects on protein function ([Table 3](#T3){ref-type="table"}). p.C889R is the first missense variant reported to affect the C889 residue. According to recent studies, VWF contains free thiols, associated with nine cysteines, including C889. These free thiols may be important for lateral self-association of VWF via thiol-disulfide exchange after secretion, thus increasing VWF size and consequently, platelet binding ability \[[@B23][@B24]\]. Other missense variants affecting the C1130 (C1130F/G/R) and W2193 (W2193R) residues have been reported in type 1/2 VWD \[[@B25][@B26][@B27]\]. Missense variants at position C1130 in the D3-domain can induce intracellular retention and impaired multimerization, as well as increased protein clearance \[[@B28][@B29]\]. A rare variant, p.N901K, was observed in patient P15 with type 1 VWD due to a known variant, p.C858W. p.N901K is registered in the Single Nucleotide Polymorphism Database (dbSNP; rs753545906) with a frequency of 0.00009 in East Asian populations and 0.00007 in combined populations. We regard p.N901K as a rare single nucleotide polymorphism (SNP) in East Asian populations rather than a variant in this patient. In addition, we could not rule out the possibility that p.C858W and p.N901K are on the same allele. A novel small insertion variant, c.2289dupG (p.S764Efs^\*^16), was also identified in a patient with type 1 VWD (P11).

Recent studies have shown that exonic deletion or duplication variants contribute to a variety of coagulation disorders; the clinical utility of MLPA analyses for detecting these large dosage variants has also been demonstrated in type 3 VWD \[[@B7][@B8][@B9][@B30][@B31]\]. However, our 2nd-line MLPA analyses in sequence variant-negative patients using sequencing did not reveal any additional large dosage variants. This could be due to the small number of patients in this study, but might also indicate that MPLA has limited diagnostic utility in Korean patients with VWD.

In summary, this study represents the first comprehensive molecular genetic investigation involving the whole coding/junction sequences of *VWF* and MLPA analyses in Korean patients with VWD. The genotype-phenotype correlations were largely in line with previous findings; however, our data provide additional evidence on the pleiotropic effect of *VWF* variants. Furthermore, the results suggested limited diagnostic utility of MLPA analyses in Korean patients with VWD.
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###### Clinical and laboratory characteristics of 22 Korean patients with VWD

![](alm-39-545-i001)

  No. Case   Sex/age (year)   VWD Type   FHx   Bleeding score   aPTT (sec)   FVIII:C (%)   VWF:Rco (IU/dL)   VWF:Ag (IU/dL)   VWF:Rco/ VWF:Ag   VWF multimer          RIPA (ohms)   Platelets (×10^9^/L)
  ---------- ---------------- ---------- ----- ---------------- ------------ ------------- ----------------- ---------------- ----------------- --------------------- ------------- ----------------------
  P1         M/5              1          No    0                41           60            22                27               0.8               Nearly absent         NT            250
  P2         F/42             3          No    12               58           7             6                 ND               NA                Nearly absent         2             231
  P3         M/36             2A         Yes   4                43           22            ND                14               NA                Loss of IMW and HMW   2             265
  P4         F/64             1          Yes   11               38           40            23                26               0.9               Normal                NT            270
  P5         F/31             2A         Yes   9                56           3             4                 14               0.3               Loss of HMW           1             210
  P6         F/7              1          No    5                29           71            19                19               1                 Normal                NT            475
  P7         M/41             2A         Yes   7                36           36            ND                25               NA                Mild loss of HMW      4             301
  P8         M/32             1          Yes   7                39           10            14                13               1.1               Mild loss of HMW      NT            286
  P9         M/26             1          No    1                44           9             13                6                2                 Normal                3             217
  P10        M/2              1          No    1                33           96            30                36               0.8               Normal                NT            222
  P11        M/19             1          No    3                49           29            42                58               0.7               Normal                NT            234
  P12        M/18             1          No    4                37           46            42                27               1.6               Normal                10            250
  P13        M/15             1          No    5                35           64            62                57               1.1               Normal                NT            240
  P14        M/19             1          Yes   1                46           38            49                24               2                 Normal                NT            240
  P15        M/45             1          Yes   11               59           3             11                6                1.8               Normal                2             378
  P16        F/20             1          No    10               35           58            71                73               1                 Normal                NT            250
  P17        F/30             2A         No    8                42           23            20                11               1.8               Loss of IMW and HMW   NT            276
  P18        F/39             1          No    9                40           15            6                 8                0.8               Absent                2             273
  P19        M/19             1          No    2                31           72            79                33               2.4               Normal                NT            239
  P20        F/33             1          No    4                25           35            15                16               0.9               Mild loss of HMW      4             262
  P21        F/5              2M         Yes   2                53           30            2                 20               0.1               Normal                2             270
  P22        F/5              2A         Yes   3                43           47            21                53               0.4               Loss of HMW           2             374

Abbreviations: P, patient; VWD, von Willebrand disease; FHx, family history; FVIII:C, FVIII coagulant activity; VWF, von Willebrand factor; VWF:Rco, VWF ristocetin cofactor activity; RIPA, ristocetin-induced platelet aggregation; AA, amino acid; ND, not detected; NT, not tested; NA, not applicable; HMW, high molecular weight multimers; IMW, intermediate molecular weight multimers.

###### *VWF* gene variants identified in 22 Korean patients with VWD
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  No. Case   VWD type   cDNA               AA                  Exon    Domain   VWFdb^†^                      ACMG classification
  ---------- ---------- ------------------ ------------------- ------- -------- ----------------------------- ---------------------
  P1         1          **c.6579G \> C**   **p.W2193C**        37      D4       (-)                           VUS
  P2         3          ND^‡^              NA                  NA      NA       NA                            NA
  P3         2A         c.3538+1G \> A     NA                  IVS26   NA       1(1)                          PV
  P4         1          **c.3389G \> A**   **p.C1130Y**        26      D3       (-)                           VUS
  P5         2A         c.2574C \> G       p.C858W             20      D′       (-)                           LPV
  P6         1          ND^‡^              NA                  NA      NA       NA                            NA
  P7         2A         c.4789C \> T       p.R1597W            28      A2       2A(11)                        PV
  P8         1          **c.2665T \> C**   **p.C889R**         20      D3       (-)                           VUS
  P9         1          c.3614G \> A       p.R1205H            27      D3       1(6), 2M (1), UC (3)          LPV
  P10        1          c.3835G \> A       p.V1279I            28      A1       1(2), 2B (1), 2M (2), 3(1)    LPV
  P11        1          **c.2289dupG**     **p.S764Efs\*16**   18      D′       (-)                           PV
  P12        1          ND^‡^              NA                  NA      NA       NA                            NA
  P13        1          ND^‡^              NA                  NA      NA       NA                            NA
  P14        1          ND^‡^              NA                  NA      NA       NA                            NA
  P15        1          c.2574C \> G       p.C858W             20      D′       (-)                           LPV
  P16        1          ND^‡^              NA                  NA      NA       NA                            NA
  P17        2A         c.3814T \> C       p.C1272R            28      A1       2A (2)                        LPV
  P18        1          c.3943C \> T       p.R1315C            28      A1       2A(1), 1(1), 2M (2), UC (1)   LPV
  P19        1          ND^‡^              NA                  NA      NA       NA                            NA
  P20        1          c.1135T \> G       p.C379G             10      D1       (-)                           LPV
                        c.7390C \> T       p.R2464C            43      C3       1(2), UC (1)                  LPV
  P21        2M         c.4121G \> T       p.R1374L            28      A1       2M (1)                        LPV
  P22        2A         c.4825G \> A       p.G1609R            28      A2       2A (3)                        PV

^†^VWD type registered in VWFdb. The number of reported patient(s) is presented in parentheses; ^‡^Multiplex-ligation dependent probe amplification analysis was performed in the seven patients without identifiable sequence variants by sequencing; no dosage variants were detected.

Novel variants are indicated in bold.

Abbreviations: P, patient; VWD, von Willebrand disease; VWF, von Willebrand factor; AA, amino acid; ND, not detected; NA, not applicable; UC, unclassified; ACMG, American College of Medical Genetics standards and guidelines; VUS, variant of uncertain significance; PV, pathogenic variant; LPV, likely pathogenic variant.

###### In silico analysis and allele frequencies of three novel missense VUS of the *VWF* gene
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  cDNA change   AA change   Exon   Domain   VWD type   SIFT       PolyPhen            AGVGD                                  dbSNP   ESP   ExAc   KRGDB
  ------------- ----------- ------ -------- ---------- ---------- ------------------- -------------------------------------- ------- ----- ------ -------
  c.2665T\>C    p.C889R     20     D3       1          Damaging   Probably damaging   Most likely interferes with function   (-)     (-)   (-)    (-)
  c.3389G\>A    p.C1130Y    26     D3       1          Damaging   Probably damaging   Most likely interferes with function   (-)     (-)   (-)    (-)
  c.6579G\>C    p.W2193C    37     D4       1          Damaging   Probably damaging   Most likely interferes with function   (-)     (-)   (-)    (-)

Abbreviations: VUS, variant of uncertain significance; AA, amino acid; VWD, von Willebrand disease; SIFT, Sorting Intolerant From Tolerant; PolyPhen, Polymorphism Phenotyping; AGVGD, Align GVGD; ESP, Exome Sequencing Project; ExAC, Exome Aggregation Consortium; KRGDB, Korean Reference Genome Database.
